UNSPSC 51373435: Citric/codeine/ipecac/potassium/promethazine/sodium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373435 Citric/codeine/ipecac/potassium/promethazine/sodium, a Commodity code, covers pharmaceutical products and related medical supplies that state and local governments procure for public health, emergency response, and community health initiatives. Recent solicitations under this code show state and local buyers acquiring naloxone (opioid antagonist), drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through authorized pharmaceutical wholesalers. Issuing bodies include county health departments, state procurement offices administering cooperative purchasing arrangements, and health system networks serving multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a significant buyer category, establishing statewide and multi-state contracts that distribute products across participating government facilities.

Recent activity spans Florida and Minnesota, with MMCAP's cooperative vehicle extending reach to Oregon and other alliance members. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response date July 26, 2026), supporting community health initiatives and funded through FEMA with compliance requirements tied to federal environmental regulations. MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) with products effective July 1, 2026 (proposal deadline March 26, 2026); evaluation weighted price competitiveness at 75 percent and mandated compliance with cGMP and Drug Supply Chain Security Act standards. Both opportunities require vendors to maintain commercial general liability coverage, E-Verify compliance, and drug-free workplace certification where applicable.